{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:25:32Z","timestamp":1793993132497,"version":"4.8.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01DK078752"],"award-info":[{"award-number":["R01DK078752"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U01DK120379"],"award-info":[{"award-number":["U01DK120379"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["DP3DK110844"],"award-info":[{"award-number":["DP3DK110844"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P30DK079626"],"award-info":[{"award-number":["P30DK079626"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","award":["1-16-ACE-47"],"award-info":[{"award-number":["1-16-ACE-47"]}],"id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Currently, no oral medications are available for type 1 diabetes (T1D). While our recent randomized placebo-controlled T1D trial revealed that oral verapamil had short-term beneficial effects, their duration and underlying mechanisms remained elusive. Now, our global T1D serum proteomics analysis identified chromogranin A (CHGA), a T1D-autoantigen, as the top protein altered by verapamil and as a potential therapeutic marker and revealed that verapamil normalizes serum CHGA levels and reverses T1D-induced elevations in circulating proinflammatory T-follicular-helper cell markers. RNA-sequencing further confirmed that verapamil regulates the thioredoxin system and promotes an anti-oxidative, anti-apoptotic and immunomodulatory gene expression profile in human islets. Moreover, continuous use of oral verapamil delayed T1D progression, promoted endogenous beta-cell function and lowered insulin requirements and serum CHGA levels for at least 2 years and these benefits were lost upon discontinuation. Thus, the current studies provide crucial mechanistic and clinical insight into the beneficial effects of verapamil in T1D.<\/jats:p>","DOI":"10.1038\/s41467-022-28826-3","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T06:05:35Z","timestamp":1646287535000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Exploratory study reveals far reaching systemic and cellular effects of verapamil treatment in subjects with type 1 diabetes"],"prefix":"10.1038","volume":"13","author":[{"given":"Guanlan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany D.","family":"Grimes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Truman B.","family":"Grayson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance A.","family":"Thielen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5861-7597","authenticated-orcid":false,"given":"Hubert M.","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9026-9999","authenticated-orcid":false,"given":"Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Kanke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai-Tu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athena A.","family":"Schepmoes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam C.","family":"Swensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4076-151X","authenticated-orcid":false,"given":"Vladislav A.","family":"Petyuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6711-071X","authenticated-orcid":false,"given":"Fernando","family":"Ovalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Sethupathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5393-2827","authenticated-orcid":false,"given":"Wei-Jun","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2869-7228","authenticated-orcid":false,"given":"Anath","family":"Shalev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,3]]},"reference":[{"key":"28826_CR1","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/s41591-018-0089-4","volume":"24","author":"F Ovalle","year":"2018","unstructured":"Ovalle, F. et al. Verapamil and beta cell function in adults with recent-onset type 1 diabetes. Nat. Med. 24, 1108\u20131112 (2018).","journal-title":"Nat. Med."},{"key":"28826_CR2","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1002\/cpz1.90","volume":"1","author":"Z Xie","year":"2021","unstructured":"Xie, Z. et al. Gene set knowledge discovery with enrichr. Curr. Protoc. 1, e90 (2021).","journal-title":"Curr. Protoc."},{"key":"28826_CR3","doi-asserted-by":"publisher","first-page":"250","DOI":"10.2337\/diabetes.53.1.250","volume":"53","author":"JP Palmer","year":"2004","unstructured":"Palmer, J. P. et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: Report of an ADA workshop, 21-22 October 2001. Diabetes 53, 250\u2013264 (2004).","journal-title":"Diabetes"},{"key":"28826_CR4","first-page":"2066","volume":"61","author":"CJ Greenbaum","year":"2012","unstructured":"Greenbaum, C. J. et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite type 1. Diabetes TrialNet Data. Diabetes 61, 2066\u20132073 (2012).","journal-title":"Diabetes TrialNet Data. Diabetes"},{"key":"28826_CR5","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.2337\/dc07-2451","volume":"31","author":"CJ Greenbaum","year":"2008","unstructured":"Greenbaum, C. J. et al. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 31, 1966\u20131971 (2008).","journal-title":"Diabetes Care"},{"key":"28826_CR6","doi-asserted-by":"publisher","unstructured":"Ebert, A., Konig, J., Frommer, L., Schuppan, D. & Kahaly, G. J. Chromogranin serves as novel biomarker of endocrine and gastric autoimmunity. J. Clin. Endocrinol. Metab. https:\/\/doi.org\/10.1210\/clinem\/dgaa288 (2020).","DOI":"10.1210\/clinem\/dgaa288"},{"key":"28826_CR7","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.2217\/bmm-2016-0091","volume":"10","author":"K Broedbaek","year":"2016","unstructured":"Broedbaek, K. & Hilsted, L. Chromogranin A as biomarker in diabetes. Biomark. Med. 10, 1181\u20131189 (2016).","journal-title":"Biomark. Med."},{"key":"28826_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jaut.2013.10.003","volume":"50","author":"PA Gottlieb","year":"2014","unstructured":"Gottlieb, P. A. et al. Chromogranin A is a T cell antigen in human type 1 diabetes. J. Autoimmun. 50, 38\u201341 (2014).","journal-title":"J. Autoimmun."},{"key":"28826_CR9","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/ni.1844","volume":"11","author":"BD Stadinski","year":"2010","unstructured":"Stadinski, B. D. et al. Chromogranin A is an autoantigen in type 1 diabetes. Nat. Immunol. 11, 225\u2013231 (2010).","journal-title":"Nat. Immunol."},{"key":"28826_CR10","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1365-2133.2012.10899.x","volume":"167","author":"Z He","year":"2012","unstructured":"He, Z. et al. Elevated serum levels of interleukin 21 are associated with disease severity in patients with psoriasis. Br. J. Dermatol. 167, 191\u2013193 (2012).","journal-title":"Br. J. Dermatol."},{"key":"28826_CR11","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.alit.2016.10.010","volume":"66","author":"H Mizutani","year":"2017","unstructured":"Mizutani, H., Tamagawa-Mineoka, R., Nakamura, N., Masuda, K. & Katoh, N. Serum IL-21 levels are elevated in atopic dermatitis patients with acute skin lesions. Allergol. Int. 66, 440\u2013444 (2017).","journal-title":"Allergol. Int."},{"key":"28826_CR12","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1172\/JCI76238","volume":"125","author":"R Kenefeck","year":"2015","unstructured":"Kenefeck, R. et al. Follicular helper T cell signature in type 1 diabetes. J. Clin. Invest. 125, 292\u2013303 (2015).","journal-title":"J. Clin. Invest."},{"key":"28826_CR13","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00125-015-3509-8","volume":"58","author":"RC Ferreira","year":"2015","unstructured":"Ferreira, R. C. et al. IL-21 production by CD4+ effector T cells and frequency of circulating follicular helper T cells are increased in type 1 diabetes patients. Diabetologia 58, 781\u2013790 (2015).","journal-title":"Diabetologia"},{"key":"28826_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1096\/fj.201901637R","volume":"34","author":"F Shao","year":"2020","unstructured":"Shao, F., Zheng, P., Yu, D., Zhou, Z. & Jia, L. Follicular helper T cells in type 1 diabetes. FASEB J. 34, 30\u201340 (2020).","journal-title":"FASEB J."},{"key":"28826_CR15","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1080\/08820139.2016.1197243","volume":"45","author":"R Baharlou","year":"2016","unstructured":"Baharlou, R. et al. Elevated levels of T-helper 17-associated cytokines in diabetes type I patients: Indicators for following the course of disease. Immunol. Invest. 45, 641\u2013651 (2016).","journal-title":"Immunol. Invest."},{"key":"28826_CR16","doi-asserted-by":"publisher","first-page":"606332","DOI":"10.3389\/fendo.2020.606332","volume":"11","author":"A Citro","year":"2020","unstructured":"Citro, A., Campo, F., Dugnani, E. & Piemonti, L. Innate immunity mediated inflammation and beta cell function: Neighbors or enemies? Front. Endocrinol. 11, 606332 (2020).","journal-title":"Front. Endocrinol."},{"key":"28826_CR17","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.2337\/db15-1333","volume":"65","author":"RJ Strawbridge","year":"2016","unstructured":"Strawbridge, R. J. et al. Soluble CD93 is involved in metabolic dysregulation but does not influence carotid intima-media thickness. Diabetes 65, 2888\u20132899 (2016).","journal-title":"Diabetes"},{"key":"28826_CR18","doi-asserted-by":"publisher","unstructured":"Menger, M. M. et al. Erythropoietin exposure of isolated pancreatic islets accelerates their revascularization after transplantation. Acta Diabetol. https:\/\/doi.org\/10.1007\/s00592-021-01760-4 (2021).","DOI":"10.1007\/s00592-021-01760-4"},{"key":"28826_CR19","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1007\/s00125-016-4067-4","volume":"59","author":"SJ Richardson","year":"2016","unstructured":"Richardson, S. J. et al. Islet cell hyperexpression of HLA class I antigens: A defining feature in type 1 diabetes. Diabetologia 59, 2448\u20132458 (2016).","journal-title":"Diabetologia"},{"key":"28826_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16327-0","volume":"11","author":"ML Colli","year":"2020","unstructured":"Colli, M. L. et al. An integrated multi-omics approach identifies the landscape of interferon-alpha-mediated responses of human pancreatic beta cells. Nat. Commun. 11, 2584 (2020).","journal-title":"Nat. Commun."},{"key":"28826_CR21","doi-asserted-by":"publisher","first-page":"988","DOI":"10.2337\/db18-0686","volume":"68","author":"MA Russell","year":"2019","unstructured":"Russell, M. A. et al. HLA class II antigen processing and presentation pathway components demonstrated by transcriptome and protein analyses of islet beta-cells from donors with type 1. Diabetes Diabetes 68, 988\u20131001 (2019).","journal-title":"Diabetes Diabetes"},{"key":"28826_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/1423-0127-18-57","volume":"18","author":"K Chen","year":"2011","unstructured":"Chen, K. et al. Overexpression of Insig-1 protects beta cell against glucolipotoxicity via SREBP-1c. J. Biomed. Sci. 18, 57 (2011).","journal-title":"J. Biomed. Sci."},{"key":"28826_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00561-0","volume":"8","author":"KF Cogger","year":"2017","unstructured":"Cogger, K. F. et al. Glycoprotein 2 is a specific cell surface marker of human pancreatic progenitors. Nat. Commun. 8, 331 (2017).","journal-title":"Nat. Commun."},{"key":"28826_CR24","doi-asserted-by":"publisher","first-page":"685524","DOI":"10.3389\/fendo.2021.685524","volume":"12","author":"T Zhang","year":"2021","unstructured":"Zhang, T. et al. Common variants in NUS1 and GP2 genes contributed to the risk of gestational diabetes mellitus. Front. Endocrinol. 12, 685524 (2021).","journal-title":"Front. Endocrinol."},{"key":"28826_CR25","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.4049\/jimmunol.1103190","volume":"189","author":"L Werner","year":"2012","unstructured":"Werner, L. et al. Identification of pancreatic glycoprotein 2 as an endogenous immunomodulator of innate and adaptive immune responses. J. Immunol. 189, 2774\u20132783 (2012).","journal-title":"J. Immunol."},{"key":"28826_CR26","doi-asserted-by":"publisher","first-page":"848","DOI":"10.2337\/db11-0955","volume":"61","author":"G Xu","year":"2012","unstructured":"Xu, G., Chen, J., Jing, G. & Shalev, A. Preventing beta-cell loss and diabetes with calcium channel blockers. Diabetes 61, 848\u2013856 (2012).","journal-title":"Diabetes"},{"key":"28826_CR27","doi-asserted-by":"publisher","first-page":"938","DOI":"10.2337\/db07-0715","volume":"57","author":"J Chen","year":"2008","unstructured":"Chen, J., Saxena, G., Mungrue, I. N., Lusis, A. J. & Shalev, A. Thioredoxin-interacting protein: A critical link between glucose toxicity and beta cell apoptosis. Diabetes 57, 938\u2013944 (2008).","journal-title":"Diabetes"},{"key":"28826_CR28","doi-asserted-by":"publisher","first-page":"440","DOI":"10.2337\/db09-0949","volume":"59","author":"J Chen","year":"2010","unstructured":"Chen, J., Fontes, G., Saxena, G., Poitout, V. & Shalev, A. Lack of TXNIP protects against mitochondria-mediated apoptosis but not against fatty acid-induced ER stress-mediated beta-cell death. Diabetes 59, 440\u2013447 (2010).","journal-title":"Diabetes"},{"key":"28826_CR29","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1096\/fj.08-111690","volume":"22","author":"J Chen","year":"2008","unstructured":"Chen, J. et al. Thioredoxin-interacting protein deficiency induces Akt\/Bcl-xL signaling and pancreatic beta cell mass and protects against diabetes. FASEB J. 22, 3581\u20133594 (2008).","journal-title":"FASEB J."},{"key":"28826_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1465-9921-13-19","volume":"13","author":"M Kudo","year":"2012","unstructured":"Kudo, M. et al. Oxidative stress induced interleukin-32 mRNA expression in human bronchial epithelial cells. Respir. Res. 13, 19 (2012).","journal-title":"Respir. Res."},{"key":"28826_CR31","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.2337\/db19-0287","volume":"68","author":"H Kallionpaa","year":"2019","unstructured":"Kallionpaa, H. et al. Early detection of peripheral blood cell signature in children developing beta-cell autoimmunity at a young age. Diabetes 68, 2024\u20132034 (2019).","journal-title":"Diabetes"},{"key":"28826_CR32","doi-asserted-by":"publisher","unstructured":"Poma, A. M. et al. Immune transcriptome of cells infected with enterovirus strains obtained from cases of type 1 diabetes. Microorganisms https:\/\/doi.org\/10.3390\/microorganisms8071031 (2020).","DOI":"10.3390\/microorganisms8071031"},{"key":"28826_CR33","doi-asserted-by":"crossref","first-page":"517","DOI":"10.7326\/0003-4819-128-7-199804010-00001","volume":"128","author":"Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial.","year":"1998","unstructured":"Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The diabetes control and complications trial research group. Ann. Intern. Med. 128, 517\u2013523 (1998).","journal-title":"Ann. Intern. Med."},{"key":"28826_CR34","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1038\/nprot.2017.054","volume":"12","author":"H Keshishian","year":"2017","unstructured":"Keshishian, H. et al. Quantitative, multiplexed workflow for deep analysis of human blood plasma and biomarker discovery by mass spectrometry. Nat. Protoc. 12, 1683\u20131701 (2017).","journal-title":"Nat. Protoc."},{"key":"28826_CR35","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1074\/mcp.T600039-MCP200","volume":"5","author":"T Liu","year":"2006","unstructured":"Liu, T. et al. Evaluation of multiprotein immunoaffinity subtraction for plasma proteomics and candidate biomarker discovery using mass spectrometry. Mol. Cell Proteom. 5, 2167\u20132174 (2006).","journal-title":"Mol. Cell Proteom."},{"key":"28826_CR36","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1074\/mcp.TIR119.001385","volume":"18","author":"J Zecha","year":"2019","unstructured":"Zecha, J. et al. TMT labeling for the masses: A robust and cost-efficient, in-solution labeling approach. Mol. Cell Proteom. 18, 1468\u20131478 (2019).","journal-title":"Mol. Cell Proteom."},{"key":"28826_CR37","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1002\/pmic.201000722","volume":"11","author":"Y Wang","year":"2011","unstructured":"Wang, Y. et al. Reversed-phase chromatography with multiple fraction concatenation strategy for proteome profiling of human MCF10A cells. Proteomics 11, 2019\u20132026 (2011).","journal-title":"Proteomics"},{"key":"28826_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6277","volume":"5","author":"S Kim","year":"2014","unstructured":"Kim, S. & Pevzner, P. A. MS-GF+ makes progress towards a universal database search tool for proteomics. Nat. Commun. 5, 5277 (2014).","journal-title":"Nat. Commun."},{"key":"28826_CR39","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.cell.2016.05.069","volume":"166","author":"H Zhang","year":"2016","unstructured":"Zhang, H. et al. Integrated proteogenomic characterization of human high-grade serous ovarian cancer. Cell 166, 755\u2013765 (2016).","journal-title":"Cell"},{"key":"28826_CR40","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.compbiolchem.2008.02.006","volume":"32","author":"ME Monroe","year":"2008","unstructured":"Monroe, M. E., Shaw, J. L., Daly, D. S., Adkins, J. N. & Smith, R. D. MASIC: A software program for fast quantitation and flexible visualization of chromatographic profiles from detected LC-MS(\/MS) features. Comput. Biol. Chem. 32, 215\u2013217 (2008).","journal-title":"Comput. Biol. Chem."},{"key":"28826_CR41","doi-asserted-by":"publisher","unstructured":"Jo, S., Xu, G., Jing, G., Chen, J. & Shalev, A. Human glucagon expression is under the control of miR-320a. Endocrinology https:\/\/doi.org\/10.1210\/endocr\/bqaa238 (2021).","DOI":"10.1210\/endocr\/bqaa238"},{"key":"28826_CR42","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1172\/JCI44198","volume":"121","author":"J Publicover","year":"2011","unstructured":"Publicover, J. et al. IL-21 is pivotal in determining age-dependent effectiveness of immune responses in a mouse model of human hepatitis B. J. Clin. Invest. 121, 1154\u20131162 (2011).","journal-title":"J. Clin. Invest."},{"key":"28826_CR43","doi-asserted-by":"publisher","first-page":"e79858","DOI":"10.1371\/journal.pone.0079858","volume":"8","author":"X Xu","year":"2013","unstructured":"Xu, X. et al. Inhibition of increased circulating Tfh cell by anti-CD20 monoclonal antibody in patients with type 1 diabetes. PLoS One 8, e79858 (2013).","journal-title":"PLoS One"},{"key":"28826_CR44","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25, 402\u2013408 (2001).","journal-title":"Methods"},{"key":"28826_CR45","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1042\/bj3420275","volume":"342","author":"HJ Kennedy","year":"1999","unstructured":"Kennedy, H. J., Rafiq, I., Pouli, A. E. & Rutter, G. A. Glucose enhances insulin promoter activity in MIN6 beta-cells independently of changes in intracellular Ca2+ concentration and insulin secretion. Biochem. J. 342, 275\u2013280 (1999).","journal-title":"Biochem. J."},{"key":"28826_CR46","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.2337\/diabetes.47.9.1436","volume":"47","author":"E Simonsson","year":"1998","unstructured":"Simonsson, E., Karlsson, S. & Ahren, B. Ca2+-independent phospholipase A2 contributes to the insulinotropic action of cholecystokinin-8 in rat islets: Dissociation from the mechanism of carbachol. Diabetes 47, 1436\u20131443 (1998).","journal-title":"Diabetes"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-28826-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-28826-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-28826-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T11:31:54Z","timestamp":1669289514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-28826-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,3]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["28826"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-28826-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,3]]},"assertion":[{"value":"5 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1159"}}